THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;THE SCRIPPS RESEARCH INSTITUTE
发明人:
ANDREW GALE,ANNETTE VON DRYGALSKI,JOHN H. GRIFFIN,LAURENT MOSNIER
申请号：
BR112016009954
公开号：
BR112016009954A2
申请日:
2014.11.04
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
The present application generally relates to methods for preventing or treating bleeding or hypocoagulation in an individual in need in need thereof, and to compositions for use in such methods. The methods comprise administering fva, preferably an apc-resistant fava (such as superfva), individually or in combination with fviia, preferably rhfviia (such as novoeven® or other active or half-life-enhanced fviia). when given in combination, fva and fviia cause a synergistic benefit when used to treat or prevent bleeding or hypocoagulation in subjects in need thereof, for example, subjects with a genetic disorder, such as hemophilia, or an acquired hemorrhagic disorder or other associated condition. bleeding or hypocoagulation, such as stroke or hemorrhagic shock, trauma, surgery, or dysmenorrhea, or individuals who produce inhibitory antibodies against procoagulants such as fviii or fix, or who have been overdosed with an anticoagulant drug , such as a direct xa inhibitor or direct thrombin inhibitor or a new oral anticoagulant (noac) or have unexplained bleeding. further, the invention relates to the use of a superfva individually or in combination with fviia or another procoagulant or prohemostatic agent to prevent, treat or reverse apc-associated bleeding, for example as a result of apc overproduction (such as severe injury and / or hemorrhagic shock) or therapy with apc or other anticoagulants, for example in the treatment of inflammatory disorders or sepsis.o presente pedido se refere de modo geral a métodos para a prevenção ou tratamento de sangramento ou hipocoagulação em um indivíduo em necessidade em necessidade do mesmo, e a composições para uso em tais métodos. os métodos compreendem administração de fva, de preferência um fva resistente a apc (tal como superfva), individualmente ou em combinação com fviia, de preferência rhfviia (tal como novoseven® ou outro fviia com atividade ou meia vida intensificada). quando administrados em combinação, fva e fviia pro
